At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 84 enrolled
Drug / intervention
brentuximab vedotin +2 moredrug
Likely dose
brentuximab vedotin 1.8 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
In Brief
A Phase 2 clinical trial evaluating brentuximab vedotin for Acute Lymphoid Leukemia and 3 related conditions. Completed, enrolled 84 participants across 29 sites.
Detailed Summary
This is an open-label, multicenter, phase 2 clinical trial to evaluate the antitumor activity of brentuximab vedotin as a single agent in patients with CD30-positive nonlymphomatous malignancies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Lymphoid Leukemia, Acute Myeloid Leukemia, Anemia, Refractory, With Excess of Blasts, Solid Tumors
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2011
First PostedOct 2011
Primary CompletionDec 2014
TodayJul 2026
First PostedOct 28, 2011
Enrollment StartOct 1, 2011
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 14.7 years ago
Interventions
brentuximab vedotindrug
1.8 mg/kg every 3 weeks by intravenous (IV) infusion
brentuximab vedotindrug
2.4 mg/kg every 3 weeks by intravenous (IV) infusion
brentuximab vedotindrug
1.2 mg/kg weekly, 3 out of 4 weeks, by intravenous (IV) infusion